A GAME CHANGER FORChronic wounds, cancer, inflammatory diseases & beyond
4-in-1 synthetic biology, cell and gene therapy platform
At Aurealis Therapeutics, we have built a unique multi-target cell and gene therapy platform to address unmet medical needs.
Discover the mode of action of our lead clinical asset AUP-16, a topical cell therapy that enables the healing of Diabetic Foot Ulcers (DFU) and other chronic, non-healing wounds.
THE TEAM, THE SCIENCE & the outcome
Meet the TEAM
At Aurealis Therapeutics we are passionate about our science to make a difference for patients. Meet the Management Team, the Scientific Advisory Board, the Board of Directors, and the Aurealis Therapeutics Team Members.
Discover the SCIENCE
Our team takes pride in mastering the most advanced cell and gene therapy science, and making work in real life, from the lab to pre-clinical and to the clinic.
See the OUTCOME
Generating pre-clinical, clinical and health-economic evidence is how we want to make a difference. Seeing non-healing wounds healing, seeing how cancer deaths can be prevented – this is what matters the most.
For Investors and Strategic Partners
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today that it has successfully completed its Phase 1 study of its lead therapeutic candidate AUP-16 in non-healing Diabetic Foot Ulcers patients, both in terms of patient recruitment and treatment. While patient observation period continues, collected data will be processed and […]Read More
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds. This announcement comes as the company successfully completed an […]Read More
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today that Mr. Laurent Décory, who joined the Board of Directors in June 2020, has accepted to join the company management team as Chief Operating Officer. Laurent will be in charge of Business Development, Health Economics, Marketing & Communication and Scientific […]Read More